drugset / Trial / NCT01034982

AZD9668 Relative Bioavailability

NCT01034982

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedSingle-groupOpen-label

Summary

The study is designed to investigate the pharmacokinetic behaviour of the free base formulation of AZD9668. The study will compared the relative bioavailability of the free base formulation at two different dose levels compared to the tosylate salt formulation.

Timeline

Start
2009-11
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule 20 mg Oral
Subject Alvelestat Small molecule 60 mg Oral